Influence of imatinib mesylate on radiosensitivity of astrocytoma cells

Anticancer Research

Volumn 29, Issue 11, 2009, Pages 4575-4578

  Ranza, Elena ^a,b   Bertolotti, A ^a,b   Facoetti, A ^a,b   Mariotti, L ^a,b   Pasi, F ^a,b   Ottolenghi, A ^a,b   Nano, R ^a,b  

^a UNIVERSITY OF PAVIA   (Italy)

^b INFN SEZIONE DI PAVIA   (Italy)

Author keywords

Astrocytoma; Gamma rays; Imatinib mesylate; PDGF receptor

Indexed keywords

IMATINIB;

ARTICLE; ASTROCYTOMA CELL; CELL PROLIFERATION; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFECT; GAMMA RADIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; RADIOSENSITIVITY; TUMOR CELL;

ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA RAYS; GLIOBLASTOMA; HUMANS; PIPERAZINES; PYRIMIDINES;

EID: 75149151882     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ and Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 1: 139-145, 2000.
2. Buchdunger E, O'Reilly T and Wood J: Pharmacology of imatinib (STI571). Eur J Cancer 38: 28-36, 2002.
3. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P and Dimetri G: Management of malignant gastrointestinal stromal tumours. Lancet Oncol 11: 655-664, 2002.
4. Newton HB: Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways. Expert Rev Anticancer Ther 5: 595-614, 2003.
5. Bihorel S, Camenisch G, Gross G, Lemaire M and Scherrmann JM: Influence of hydroxyurea on imatinib mesylate (Gleevec) transport at the mouse blood-brain barrier. Drug Metab Dispos 12: 1945-1949, 2006.
6. Johansson Swartling F: Identifying candidate genes involved in brain tumor formation. Ups J Med Sci 1: 1-38, 2008.
7. Strawn LM, Mann E, Elliger SS, Chu LM, Germain LL, Niederfellner G, Ullrich A and Shawver LK: Inhibition of glioma cell growth by a truncated platelet-derived growth factor-beta receptor. J Biol Chem 33: 21215-21222, 1994.
8. Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, Van Etten RA, Dörken B and le Coutre P: Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cell Mol Dis 34: 181-185, 2005.
9. Salgaller ML and Liau LM: Current status of clinical trials for glioblastoma. Rev Recent Clin Trials 3: 265-281, 2006.
10. Nieder C, Grosu AL, Mehta MP, Andratschke N and Molls M: Treatment of malignant gliomas: radiotherapy, chemotherapy and integration of new targeted agents. Expert Rev Neurother 4: 691-703, 2004.
11. Oertel S, Krempien R, Lindel K, Zabel A, Milker-Zabel S, Bischof M, Lipson KE, Peschke P, Debus J, Abdollahi A and Huber PE: Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec). Strahlenther Onkol 182: 400-407, 2006.
12. Rössler J, Zambrzycka I, Lagodny J, Kontny U and Niemeyer CM: Effect of STI-571(imatinib mesylate) in combination with retinoic acid and gamma-irradiation on viability of neuroblastoma cells. Biochem Biophys Res Commun 342: 1405-1412, 2006.
13. Ranza E, Mazzini G, Facoetti A and Nano R: Evaluation of imatinib mesylate (STI571) effects on glioblastoma cell proliferation and migration. Anticancer Res 28: 3417, 2008.